Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. - Wikidata - wikimedia - TriplyDB

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

http://www.wikidata.org/entity/Q34088756

about

Cytogenetic features in myelodysplastic syndromes The blind men and the AML elephant: can we feel the progress?Spotlight on decitabine for myelodysplastic syndromes in Chinese patients Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments Predicting response to epigenetic therapy GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells The role of lenalidomide in the management of myelodysplasia with del 5q.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.Epigenetic changes in the myelodysplastic syndrome.DNA hypomethylation in cancer cells.Epigenetic therapies in MDS and AML Decitabine in the treatment of myelodysplastic syndromes.Clinical development of demethylating agents in hematology Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes Epigenetic cancer therapies: DNA methyltransferase inhibitors.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.DNA methylation in haematological malignancies: the role of decitabine.Arsenic trioxide for the treatment of myelodysplastic syndromes.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia Emerging treatments in acute myeloid leukaemia.A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment.Demethylation of DNA by decitabine in cancer chemotherapy.SGI-110: DNA Methyltransferase Inhibitor Oncolytic DNA hypo-methylating agents and sickle cell disease.Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.The silence of the genes: epigenetic disturbances in haematopoietic malignancies.Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study Epigenetic therapy with decitabine for myelodysplasia and leukemia.Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma.The role of decitabine in the treatment of myelodysplastic syndromes.Clinical relevance of cytogenetics in myelodysplastic syndromes.The use of hypomethylating agents in the treatment of hematologic malignancies.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

P2860

Q24644654-D73BAF22-DD45-48B8-8C93-0AACC655D612 Q26749614-B5ED316E-083A-4E33-AE5D-D8C50CD4BE8D Q26778454-40CB1AD9-503E-405F-88B6-ABA54F7B7438 Q26828724-FCF11D69-4B84-42C8-8A3E-4F7101488197 Q27027751-C9928E93-0162-4F93-A383-5C070EB46D57 Q28477278-31C2053C-FE3F-4905-BB0F-6B824F92C53B Q33378398-815F8289-DD11-442D-BD1F-C330E040734A Q33393647-7CE28BBA-C90F-4B33-8683-C8153DB6F163 Q33405278-AA509C11-967B-40FB-869D-98CEA82DDB23 Q33431466-0ACAFEC6-C80A-43F6-B2A7-30001B36FEBC Q33767309-05BE0464-BEE9-4D01-BFD4-CD62E58D901E Q33862334-AF7DCBB2-7CC8-4EF3-BC67-416C2CEB4E7E Q33863567-19FB5094-2B8D-4A9B-9A0E-A043BC76B23C Q34088403-D237FFAA-1439-4C7C-B3A2-6131FD9DA8B1 Q34395179-81FF4D31-F065-4FCC-9736-7D2AB5393293 Q34400180-9A900BEB-CE61-4EC0-964E-9198FFA42CDE Q34660829-2F39313F-F06A-492F-821B-0AECC5E0FDA3 Q34768789-F18C68A2-DA04-4DB9-9B2C-CA6998103CCE Q35186892-AAD09717-F0BE-4CA7-A163-91F7DA3283E4 Q35563121-3D6E3796-91CF-4B6E-872B-4404F13F7D6D Q35594048-DED1F2AE-0463-40C6-BF43-F2C3F9D91126 Q35688178-BE6558BE-D0A5-40DE-8B21-D5CEA96A023A Q35742564-01C499B3-B93F-4CA6-B78D-4AD9BC5E298D Q35779278-8A39260A-ED8B-4BB2-9B17-E5A3C1571A84 Q35794439-7DF9C35D-3914-4616-9266-43FC9D7A34F7 Q35809447-3B7F3F7C-58B4-47F5-9B8D-914C4575EB42 Q35843658-5FEDAD3C-844E-4240-87AC-6520C7B52ABB Q35854709-9B3BA037-8F3F-4598-8F5F-E0359600D452 Q35870510-DA9ABDC6-C01F-4A71-B7EA-D6018654A790 Q35888669-333898F3-2B1D-4D54-91C2-35749B1836A3 Q36055095-328CB8C5-A803-4333-BAA2-9E85D6B66A48 Q36066276-4D155A8E-53E6-4727-AB75-122D1FB7560E Q36140902-5810969D-7139-4C58-8ABC-9A14D3D9FDED Q36327153-A1C47BA4-A94F-4BE0-A995-B878EE57C554 Q36429559-A521476A-9A35-4B1E-A524-A7F70CCB76FD Q36509996-1CF6AEED-826F-4684-AB60-D8A90B63CCC9 Q36681327-E02C064A-C446-4127-B081-03AF30B866B6 Q36721793-32441552-EE13-4832-AF78-B57C27C9AF37 Q36929658-398D41A1-314E-421F-8B35-C64FE92E8D88 Q37263146-E52154B8-5C4C-4F44-90AA-CAE4E427508A

P2860

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

http://www.wikidata.org/entity/Q34088756

description

2001 nî lūn-bûn

@nan

2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@ast

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@en

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@nl

type

label

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@ast

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@en

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@nl

prefLabel

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@ast

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@en

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@nl

P1433

Q34088756-52C08F4A-64AA-45A8-BE8B-A9F9E2D22F80

P1476

Q34088756-CAC86F0A-2F66-4D25-8015-FA4E23397BA2

P2093

Q34088756-3C4DD0A7-EE76-474C-9570-267EB22AA794

Q34088756-46C39B91-D12A-46E4-8E57-16189B3B43FC

Q34088756-48BC871B-14E8-42E7-AFC1-8CF80439DB5C

Q34088756-4A60ECCA-AA2B-40F0-9582-B35C7DACD5C8

Q34088756-87F04310-A2AA-4C75-8CE9-28B5A76F0678

Q34088756-9A6A8461-5782-41FF-9A36-60B12DBE6A27

Q34088756-AF87ED58-3693-4FED-B66F-5BA3153DBACB

Q34088756-F1B31FFA-3D10-42AC-8513-D933C41CF545

P2860

Q34088756-13299659-9E95-41C1-BA56-FB461939F283

Q34088756-18DB7A7F-34CA-4E3E-9423-70F41659C0A7

Q34088756-1D1CCDE5-F7CC-40D2-B0EE-9DEC298FD63A

Q34088756-1D352F23-9A97-4E3E-91BF-414491B85B37

Q34088756-21069C69-E5A9-48B0-9588-EB84737D08F9

Q34088756-55B5D719-FEAA-482F-B067-04269B21C8C3

Q34088756-6AB1CEA9-68F2-4329-A82A-3DC91C950D81

Q34088756-712AACC1-7B4E-4CD1-B6A5-D05B66ACCE4F

Q34088756-72E1C4CF-035E-404D-8355-342318BDF1E7

Q34088756-7464B45E-3978-40FC-A807-1828EAB290CB

P304

Q34088756-D29616BF-000F-4337-900E-9931A7F31178

P31

Q34088756-E5679CFE-3118-4A03-AE53-DB4ED84E149D

P356

Q34088756-BB7112A5-65E1-4720-AFBA-BAEED518726F

P407

Q34088756-B20BE868-755B-41B1-A86D-96672D91965B

P433

Q34088756-2D5E7011-A48A-490D-B672-509AABA469C4

P478

Q34088756-A00FA704-D1FD-457E-AC2A-946A1A42A920

P577

Q34088756-EF196F54-71F7-4B5C-896D-9D89DF295BBA

P5875

Q34088756-4EC3DCB3-225C-497B-A12A-2CE841359F76

P698

Q34088756-784D317F-D19D-4437-9C0C-5FD5EF6F5463

P921

Q34088756-E4B10D5B-B919-4FDC-9353-E00BF7227477

P356

J.1365-2141.2001.02933.X

P1433

British Journal of Haematology

P1476

Cytogenetic responses in high- ...... ibitor 5-aza-2'-deoxycytidine.

@en

P2093

A Bosly

http://www.w3.org/2001/XMLSchema#string

A Ferrant

http://www.w3.org/2001/XMLSchema#string

C Ravoet

http://www.w3.org/2001/XMLSchema#string

G Verhoef

http://www.w3.org/2001/XMLSchema#string

M Andre

http://www.w3.org/2001/XMLSchema#string

M Lübbert

http://www.w3.org/2001/XMLSchema#string

P Wijermans

http://www.w3.org/2001/XMLSchema#string

R Kunzmann

http://www.w3.org/2001/XMLSchema#string

P2860

The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome

Nonparametric Estimation from Incomplete Observations

Proposals for the classification of the myelodysplastic syndromes

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome.

DNA hypomethylation leads to elevated mutation rates.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.

A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.

P304

349-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.2001.02933.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11815982

http://www.w3.org/2001/XMLSchema#string

P698

11529854

http://www.w3.org/2001/XMLSchema#string

P921

DNA methylation